RxDoctor Payments Data

Ashkan Naraghi, MD

Internal Medicine · Los Angeles, CANPI 1982813630

Payments from drug & device makers

$164,510in general payments, 2019–2025

Across 823 payments — averaging $199.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$147K
  • Mylan Specialty L.p.$3K
  • GSK$2K
  • Pinnacle Biologics, Inc$2K
  • Amgen$2K
  • Boehringer Ingelheim$1K
  • plus $7K from 53 others

What the payments were for

  • Consulting fees$2,9902%
  • Speaking & faculty fees$136,62583%
  • Travel & lodging$3,1122%
  • Food & beverage$21,48213%
  • Education$3010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)254$146,542
Mylan Specialty L.p.22$3,474
GSK102$2,044
Pinnacle Biologics, Inc9$1,976
Amgen82$1,666
Boehringer Ingelheim55$1,308
Regeneron Healthcare Solutions, Inc.20$647
Baxter Healthcare20$489
Jazz Pharmaceuticals Inc.16$453
United Therapeutics Corporation13$339
Mallinckrodt Hospital Products Inc.11$327
Electromed, Inc.19$324
Harmony Biosciences LLC8$322
Genentech USA, Inc.18$298
Insmed, Inc.10$291
Lilly USA, LLC13$281
Johnson & Johnson13$261
AbbVie(2 entities)7$255
Advanced Respiratory, Inc7$245
Pfizer12$244
Sanofi11$240
Pulmonx Corporation5$230
Philips North America LLC9$209
Paratek Pharmaceuticals, Inc.10$198
Novartis8$187
Bausch Health US, LLC8$186
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$137
Axsome Therapeutics, Inc.5$122
Sanofi-aventis U.S. LLC1$100
Idorsia Pharmaceuticals US Inc5$97
E.r. Squibb & Sons, L.L.C.4$83
Exact Sciences3$80
Viatris Specialty LLC3$80
ANI Pharmaceuticals, Inc.3$78
Shionogi Inc2$58
Alnylam Pharmaceuticals Inc.2$47
La Jolla Pharmaceutical Company2$46
Grifols USA, LLC2$44
Actelion Pharmaceuticals US, Inc.2$42
Edwards Lifesciences1$39
Itamar Medical Inc2$37
Sumitomo Pharma America, Inc.1$30
Gilead1$28
Biohaven Pharmaceutical Holding Company Ltd.1$25
Inspire Medical Systems, Inc.1$25
Teva Pharmaceuticals USA, Inc.1$24
Mallinckrodt Enterprises LLC1$23
Esperion Therapeutics, Inc.1$23
Sunovion Pharmaceuticals Inc.1$21
Corcept Therapeutics1$20
Abbott1$20
Optos, Inc.1$19
Heartflow, Inc.1$19
Valeritas, Inc.1$19
Kowa Pharmaceuticals America, Inc.1$18
Merck1$18
Novo Nordisk1$17
Tactile Systems Technology Inc1$16
Currax Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,510 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,050,188
Medicare patients
958
Services billed
11,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$362,501
Breztri AerosphereBudesonide/Glycopyr/Formoterol245$154,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter136$127,619
TezspireTezepelumab-Ekko21$122,178
EliquisApixaban162$88,178
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr115$73,462
Pirfenidone14$31,336
Spiriva RespimatTiotropium Bromide38$29,659
SantylCollagenase Clostridium Hist.38$22,708
Atrovent HfaIpratropium Bromide37$20,385
ProliaDenosumab11$18,767
Breo ElliptaFluticasone/Vilanterol29$17,905
JanuviaSitagliptin Phosphate11$16,402
JardianceEmpagliflozin26$15,375
Albuterol Sulfate HfaAlbuterol Sulfate324$13,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Jardiance, Stiolto Respimat, Combivent Respimat$1,308$425,664118 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$146,542$286,163295 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,044$218,987280 claims
PfizerEliquis$244$88,178162 claims
AmgenProlia$1,666$18,76711 claims
MerckJanuvia$18$16,40211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →